DRL gears up for biosimilar push, consumer health growth post record FY25
Dr Reddy’s stock rose 5.5% in six sessions post-Q4 results, outperforming the BSE Healthcare index. Strong revenue growth, biosimilar launches, and semaglutide portfolio support long-term prospects despite Revlimid taper and reduced target prices by (...)
Site référencé: The Economic Times
The Economic Times
NRI Talk : Why NRIs are exploring Vietnam, Indonesia, and Africa for tactical growth, Sreepriya NS decodes
20/05/2025
Golden Crossovers : These 3 stocks signal bullishness on May 20
20/05/2025
Stocks to buy in 2025 : BHEL, Divi’s Laboratories among 5 stocks that could give 10-40% return
20/05/2025
Q4 results today : Hindalco among 145 companies to announce earnings on Tuesday
20/05/2025
Borana Weaves IPO opens for subscription with healthy GMP. Should you bid ?
20/05/2025
How will higher anchor investor allocation impact lower rated bond market ?
20/05/2025
